Human interleukin-2

The 2024 ESMO Annual Congress in Barcelona showcased Biosyngen's gene-modified TILs from liver cancer biopsies, with BRG01 in Phase II trials for solid tumors. Biosyngen's TIL platform includes efficient TIL manufacturing, stable gene modification, enhanced TIL persistence, and strong antitumor efficacy without IL-2.

29% of heavily pre-treated platinum-resistant ovarian cancer patients showed anti-tumor responses with TransCon IL-2 β/γ plus chemotherapy, with generally well-tolerated side effects.

Initial data from Ascendis Pharma's Phase 1/2 IL-Believe Trial show 29% (4/14) anti-tumor responses in heavily pre-treated platinum-resistant ovarian cancer patients treated with TransCon IL-2 β/γ plus chemotherapy, with the combination generally well-tolerated.

Article references on neuroblastoma treatments, including advances in therapy, risk classification, and immunotherapy, with focus on NK cell-based strategies and clinical trials.

TILT Biotherapeutics presents Phase I data on TILT-123, an intravenous oncolytic adenovirus therapy for advanced solid cancers, at ESMO 2024, demonstrating safety and tumor transduction.

Innovent Biologics' PD-1/IL-2a-bias Bispecific Antibody Fusion Protein (IBI363) received Fast Track Designation from the FDA for treating melanoma. Phase 1/2 trials in China, the US, and Australia show promising efficacy, with 29.7% ORR and 73.0% DCR in melanoma patients previously treated with immunotherapy. IBI363 aims to address unmet needs for immunotherapy-resistant melanoma.

FDA approved lifileucel (Amtagvi), the first TIL-based cancer treatment for advanced melanoma, marking a milestone in cellular therapy. Derived from patients' tumor T cells, lifileucel showed significant tumor reduction in trials. Despite side effects, its approval heralds a new era in treating solid tumors, with ongoing research to enhance efficacy and broaden applications.

Sanofi's cancer drug SAR444245, part of a $2.5B acquisition, returns to Phase 1/2 testing due to lower than expected efficacy, leading to a €1.6B impairment. The IL-2 based therapy aims for a safer, effective cancer treatment amidst competition from other biotechs innovating IL-2 therapies.

Eflornithine (Iwilfin) was FDA-approved on December 13, 2023, for high-risk neuroblastoma patients post-therapy response. It's the first therapy aimed at reducing relapse risk in pediatric patients. Dosage varies by body surface area, with warnings for serious side effects like myelosuppression and hepatotoxicity.